These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38642937)

  • 1. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
    Wang L; Luo Y; Ren S; Zhang Z; Xiong A; Su C; Zhou J; Yu X; Hu Y; Zhang X; Dong X; Meng S; Wu F; Hou X; Dai Y; Song W; Li B; Wang ZM; Xia Y; Zhou C
    J Thorac Oncol; 2024 Mar; 19(3):465-475. PubMed ID: 37879536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
    Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
    Bishnoi S; Kotasek D; Aghmesheh M; Yau T; Cosman R; Prawira A; Moore M; Chan SL; Mant A; Eek R; Zielinski R; Su R; Pan Z; Ma Y; Li F; Li P; Tse AN
    Cancer; 2024 Jun; 130(11):1991-2002. PubMed ID: 38404184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
    Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
    Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
    Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
    Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
    Zhao Y; Ma Y; Zang A; Cheng Y; Zhang Y; Wang X; Chen Z; Qu S; He J; Chen C; Jin C; Zhu D; Li Q; Liu X; Su W; Ba Y; Hao Y; Chen J; Zhang G; Qu S; Li Y; Feng W; Yang M; Liu B; Ouyang W; Liang J; Yu Z; Kang X; Xue S; Yang G; Yan W; Yang Y; Liu Z; Peng Y; Fanslow B; Huang X; Zhang L; Zhao H
    J Hematol Oncol; 2023 May; 16(1):50. PubMed ID: 37158938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
    Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G
    Sheng X; Yan X; Chi Z; Si L; Cui C; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Wang K; Tang X; Zhou H; Wu H; Feng H; Yao S; Flaherty KT; Guo J
    J Clin Oncol; 2019 Nov; 37(32):2987-2999. PubMed ID: 31403867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    Kim TW; Bedard PL; LoRusso P; Gordon MS; Bendell J; Oh DY; Ahn MJ; Garralda E; D'Angelo SP; Desai J; Hodi FS; Wainberg Z; Delord JP; Cassier PA; Cervantes A; Gil-Martin M; Wu B; Patil NS; Jin Y; Hoang T; Mendus D; Wen X; Meng R; Cho BC
    JAMA Oncol; 2023 Nov; 9(11):1574-1582. PubMed ID: 37768658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
    Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
    Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
    ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CX-072 (pacmilimab), a Probody
    Naing A; Thistlethwaite F; De Vries EGE; Eskens FALM; Uboha N; Ott PA; LoRusso P; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Randhawa M; Durm G; Gil-Martin M; Stroh M; Hannah AL; Arkenau HT; Spira A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
    Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
    Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
    Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
    Jimeno A; Moore KN; Gordon M; Chugh R; Diamond JR; Aljumaily R; Mendelson D; Kapoun AM; Xu L; Stagg R; Smith DC
    Invest New Drugs; 2019 Jun; 37(3):461-472. PubMed ID: 30229512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
    Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.